255 related articles for article (PubMed ID: 9149031)
1. Tamoxifen-associated venous thrombosis and activated protein C resistance due to factor V Leiden.
Weitz IC; Israel VK; Liebman HA
Cancer; 1997 May; 79(10):2024-7. PubMed ID: 9149031
[TBL] [Abstract][Full Text] [Related]
2. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
[TBL] [Abstract][Full Text] [Related]
3. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
4. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation.
Manten B; Westendorp RG; Koster T; Reitsma PH; Rosendaal FR
Thromb Haemost; 1996 Oct; 76(4):510-3. PubMed ID: 8902987
[TBL] [Abstract][Full Text] [Related]
5. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
Kovac M; Kovac Z; Tomasevic Z; Vucicevic S; Djordjevic V; Pruner I; Radojkovic D
Eur J Intern Med; 2015 Jan; 26(1):63-7. PubMed ID: 25592075
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
[TBL] [Abstract][Full Text] [Related]
7. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
8. Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
Olave T; Cornudella R; Homs C; Azaceta G; Tirado I; Gutierrez M
Haematologica; 1998 Apr; 83(4):378-80. PubMed ID: 9592991
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Guasch JF; Lensen RP; Bertina RM
Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
[TBL] [Abstract][Full Text] [Related]
10. Female gender and resistance to activated protein C (FV:Q506) as potential risk factors for thrombosis after elective hip arthroplasty.
Svensson PJ; Benoni G; Fredin H; Björgell O; Nilsson P; Hedlund U; Nylander G; Bergqvist D; Dahlbäck B
Thromb Haemost; 1997 Sep; 78(3):993-6. PubMed ID: 9308742
[TBL] [Abstract][Full Text] [Related]
11. [Prevalence of genetic prothrombotic factors (factor V Leiden and II20210 prothrombin mutation) in glomerular nephropathies with or without thrombosis].
Martínez Ara J; Gómez Rioja R; Riñón C; García Muñoz MS; Ruiz Caravaca ML; Miguel JL
Nefrologia; 2000; 20(2):139-44. PubMed ID: 10853194
[TBL] [Abstract][Full Text] [Related]
12. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H
Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526
[TBL] [Abstract][Full Text] [Related]
14. Life threatening pulmonary embolus in a factor V Leiden carrier on oral contraceptives: a case report.
Saif MW; Volpe BT; Dailey M; Tsongalis GJ
Conn Med; 1997 Jun; 61(6):333-7. PubMed ID: 9238827
[TBL] [Abstract][Full Text] [Related]
15. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
Miñano A; Ordóñez A; España F; González-Porras JR; Lecumberri R; Fontcuberta J; Llamas P; Marín F; Estellés A; Alberca I; Vicente V; Corral J
Haematologica; 2008 May; 93(5):729-34. PubMed ID: 18387978
[TBL] [Abstract][Full Text] [Related]
16. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
[TBL] [Abstract][Full Text] [Related]
17. Resistance to activated protein C: a major cause of inherited thrombophilia.
Jensen R; Ens GE
Clin Lab Sci; 1997; 10(4):219-22. PubMed ID: 10169621
[TBL] [Abstract][Full Text] [Related]
18. Factor V Leiden and thrombotic complications in heparin-induced thrombocytopenia.
Lee DH; Warkentin TE; Denomme GA; Lagrotteria DD; Kelton JG
Thromb Haemost; 1998 Jan; 79(1):50-3. PubMed ID: 9459322
[TBL] [Abstract][Full Text] [Related]
19. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis.
Mandel H; Brenner B; Berant M; Rosenberg N; Lanir N; Jakobs C; Fowler B; Seligsohn U
N Engl J Med; 1996 Mar; 334(12):763-8. PubMed ID: 8592550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
